The suppression of Th2 cytokine production from Th2 cells by the oral administration of CAE likely regulates the class switch to IgE and the infiltration of immune cells into inflammation sites, leading to a decrease in serum IgE levels and the reduction in allergy symptoms. The gene discussed is IGHE; the disease is allergic disease.